AstraZeneca/Daiichi Sankyo ADC Pact Continues Clinical Success In Breast Cancer
Early TNBC Efficacy Signs From Datopotamab Deruxtecan
While much earlier in its development, the drug may be able to rival Gilead’s Trodelvy, which also targets TROP2 and showed similar response rates.
You may also be interested in...
The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.
Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker